Neuphoria Therapeutics (NEUP) Enterprise Value (2022 - 2026)

Neuphoria Therapeutics (NEUP) has reported Enterprise Value for 5 consecutive years, with $487.9 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Enterprise Value fell 30.4% year-over-year to $487.9 million in Q1 2026; TTM through Mar 2026 was $487.9 million, a 30.4% decrease from a year earlier, with the FY2025 full-year figure at $865.3 million, down 23.23% from the prior year.
• Enterprise Value was $487.9 million for Q1 2026 at Neuphoria Therapeutics, up from $461.4 million in the prior quarter.
• Over five years, Enterprise Value peaked at $9.4 billion in Q2 2022 and troughed at $423.2 million in Q4 2024.
• A 5-year average of $2.0 billion and a median of $1.1 billion in 2024 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value tumbled 83.9% in 2024 and soared 124.39% in 2025, its largest moves.
• Over 5 years, Enterprise Value stood at $9.4 billion in 2022, then slumped by 76.64% to $2.2 billion in 2023, then tumbled by 80.8% to $423.2 million in 2024, then rose by 9.02% to $461.4 million in 2025, then gained by 5.75% to $487.9 million in 2026.
• The last three Enterprise Value figures came in at $487.9 million (Q1 2026), $461.4 million (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.